Navigation Links
CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinson's Disease Motor Symptoms
Date:12/19/2007

CLEVELAND, Dec. 19 /PRNewswire/ -- Cleveland Medical Devices Inc. (CleveMed) announced that it has been awarded $1.5 million in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS). The grant will fund further development and clinical validation of Kinesia(TM), a quantitative motor assessment system for evaluating Parkinson's disease symptom severity. The initiative includes a large multi-center clinical trial with University Hospitals of Cleveland, the University of Cincinnati, and The Clinical Neuroscience Center in Detroit, Michigan as the participating centers. The trial will aid in development of Kinesia for continuous symptom monitoring in patients' homes, as well as further validate the correlation between the device and the Unified Parkinson's Disease Rating Scale (UPDRS).

Kinesia is a compact lightweight system worn on a patient's wrist and hand. The device monitors three-dimensional motion and electrical muscle activity (EMG) to objectively quantify the severity of Parkinson's disease symptoms, such as tremor, bradykinesia (slowed movements) and dyskinesias (wild, involuntary movements). Patients follow on screen video instruction while data is wirelessly transmitted to a computer to enhance user safety and comfort.

"Objective quantification of Parkinson's disease symptoms such as tremor, bradykinesia, and dyskinesias is important in light of new pharmaceutical trials and novel therapies such as deep brain stimulation," said Dr. Alberto Espay, Neurologist at the University of Cincinnati Movement Disorders Center. "The technology should prove useful for quantifying symptoms in-clinic and tracking symptom fluctuation patterns at patients' homes to more effectively modulate treatments, ultimately improving quality of life for individuals with Parkinson's disease."

A previous clinical study involving 60 Parkinson's patients showed good correlation between Kinesia and the UPDRS. The UPDRS, a subjective assessment scale, is the current standard in rating Parkinson's symptom severity. "Kinesia is being developed as a standardized platform to measure motor symptoms and meets the clinical need for quantifying and tracking symptoms more objectively," said Joseph P. Giuffrida, PhD, Director of CleveMed's Division of Movement Disorders. "Using Kinesia with the UPDRS will give clinicians detailed information for basing treatment options, such as medication dosage and timing." This funding will be used to upgrade the system for home use, further validate correlations between Kinesia and the UPDRS and demonstrate efficacy of home monitoring over longer periods of time, such as days, weeks or months, instead of just the snapshot that clinicians see in a typical office exam.

About CleveMed - CleveMed was founded with the goal of developing innovative telemetry devices for a variety of medical applications. Today, CleveMed is developing and pioneering the use of novel wireless monitoring systems for high growth neurology and rehabilitation applications, including brain monitoring, sleep disorders and movement disorders. Through these

innovations, CleveMed has developed a growing range of products that address the needs of the medical, research and academic communities.


'/>"/>
SOURCE CleveMed
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... Precision Periodontics ... offering LANAP® and LAPIP™ laser treatments. Drs. Hoge and Zalewsky are members of ... minimally invasive and less painful option that produces real results. , "Like many ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... which includes executive, engineering and manufacturing functions to The LaunchPort™ Accelerator at the ... provide a full range of manufacturing and business services to its Residents. ...
(Date:9/21/2017)... ... September 21, 2017 , ... Colpitts ... relaunch of the portal includes new features that facilitate streamlined and compliant communication, ... to remain at the forefront of medical advancements, they rely on efficiencies to ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... bright neon green this month, the response was swift and efficient thanks to ... RRWQG ). RRWQG is made up of more than 50 stakeholders, including officials ...
Breaking Biology Technology:
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):